Acetylsalicylic acid therapy: Influence of metformin use and other variables on urinary 11-dehydrothromboxane B₂ levels

详细信息    查看全文

• 作者：Lillian Harboe Gon莽alves ; Marcos Vin铆cius Ferreira Silva ; Rita Carolina Figueiredo Duarte ; Luci Maria S. Dusse ; Ana Paula Fern ; es ; Adriana A. Bosco ; Karina Braga Gomes ; Maria das Gra莽as Carvalho
• 关键词：Acetylsalicylic acid ; Metformin ; Diabetes mellitus ; 11-Dehydrothromboxane B2
• 刊名：Clinica Chimica Acta
• 出版年：15 February, 2014
• 年：2014
• 卷：429
• 期：Complete
• 页码：76-78
• 全文大小：196 K

文摘

Background

The effect of acetylsalicylic acid (ASA) may be measured through the analysis of urinary concentrations of 11-dehydrothromboxane B₂ (11-dhTXB₂), a metabolite of thromboxane A₂, which is a potent platelet aggregant agent. It has been suggested that metformin (an oral antidiabetic drug) could improve oxidative stress and control platelet activation in type 2 diabetic patients, potentially reducing cardiovascular risk. We determined the concentrations of urinary 11-dhTXB₂ in type 2 diabetic patients taking ASA and its concentrations with metformin use and several other clinical variables (hypertension, age, gender, smoking, body mass index, insulin and statin use), considering a reduction of at least 75% in the concentrations of this marker as a target, compared to results before ASA intake.

Methods

Urinary concentrations of 11-dhTXB₂ of 81 type 2 diabetic patients were measured before and at 15 days taking 100 mg of aspirin daily.

Results

Most patients who presented a reduction of 11-dhTXB₂ above 75% were under metformin use. This reduction was achieved in 51.5% of patients taking this drug, against 20.0% in the patients who were not (p = 0.027). The analysis of the other variables did not show a significant difference. The use of metformin appears to play a role in the reduction of 11-dhTXB₂ concentrations in type 2 diabetic patients.

Conclusion

According to previous reports, hyperglycemia control seems to be a determinant factor for the success of ASA therapy, given the influence of metformin in the reduction of 11-dhTXB₂ concentrations.